Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Kjersti E. Hestetun"'
Autor:
Havjin Jacob, Luka Stanisavljevic, Kristian Eeg Storli, Kjersti E. Hestetun, Olav Dahl, Mette P. Myklebust
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-9 (2018)
Abstract About 20 percent of TNM-stage II colon cancer patients who are treated by surgical resection develop recurrence, and adjuvant chemotherapy in this group is still debated among researchers and clinicians. Currently, adverse histopathological
Externí odkaz:
https://doaj.org/article/9dd3caffa57b43dc8719f849893eb89b
Autor:
Olav Dahl, Kjersti E. Hestetun, Yvonne Müller, Mette Pernille Myklebust, Nina Benedikte Rosenlund, Kristine Aasebø
Publikováno v:
Modern Pathology. 34:161-170
Mismatch repair (MMR) deficiency is an indicator of good prognosis in localized colon cancer but also associated with lack of expression of caudal-type homeobox transcription factor 2 (CDX2) and high tumor grade; markers that in isolation indicate a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45260aecf957bb98d63f9d7232769001
https://doi.org/10.1038/s41379-020-0634-9
https://doi.org/10.1038/s41379-020-0634-9
Autor:
MAGNUS BERLE, KJERSTI E. HESTETUN, HEIDRUN VETHE, SIMONA CHERA, JOAO A. PAULO, OLAV DAHL, METTE PERNILLE MYKLEBUST
Publikováno v:
Cancer Genomics & Proteomics
Cancer Genomics Proteomics
Cancer Genomics Proteomics
Background/Aim: Better stratification of the risk of relapse will help select the right patients for adjuvant treatment and improve targeted therapies for patients with colon cancer. Materials and Methods: To understand why a subset of tumors relapse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8115e0a446aca77b0c83b45bbd167e0b
https://hdl.handle.net/11250/3047463
https://hdl.handle.net/11250/3047463
Autor:
Kjersti E. Hestetun, Luka Stanisavljevic, Kristian Eeg Storli, Mette Pernille Myklebust, Havjin Jacob, Olav Dahl
Publikováno v:
Oncotarget
// Havjin Jacob 1 , Luka Stanisavljevic 2 , Kristian Eeg Storli 3 , Kjersti E. Hestetun 1 , Olav Dahl 1, 2 and Mette P. Myklebust 2 1 Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway 2 Department of Oncology a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4ed3cb2068c066c4e6f1cd6b19315f4
https://doi.org/10.18632/oncotarget.21237
https://doi.org/10.18632/oncotarget.21237
Publikováno v:
Annals of Oncology. 31:S230
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8549a8d0ea5e3b23af79beadb612b5b2
https://doi.org/10.1016/j.annonc.2020.04.051
https://doi.org/10.1016/j.annonc.2020.04.051
Autor:
Mette Pernille Myklebust, Olav Dahl, Kristian Eeg Storli, Luka Stanisavljevic, Kjersti E. Hestetun, Havjin Jacob
Publikováno v:
Scientific Reports
Scientific Reports, Vol 8, Iss 1, Pp 1-9 (2018)
Scientific Reports, Vol 8, Iss 1, Pp 1-9 (2018)
About 20 percent of TNM-stage II colon cancer patients who are treated by surgical resection develop recurrence, and adjuvant chemotherapy in this group is still debated among researchers and clinicians. Currently, adverse histopathological and clini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40ad8de0266b71add3f9e6afc901d8dc
https://doi.org/10.1038/s41598-018-24519-4
https://doi.org/10.1038/s41598-018-24519-4
Nuclear maspin expression as a predictive marker for fluorouracil treatment response in colon cancer
Publikováno v:
Acta Oncologica. 54:470-479
Background. Maspin is a member of the serpin family of protease inhibitors whose function in colorectal cancer is not fully understood. The objective of this study was to determine whether level of maspin expression could have prognostic or predictiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::254c174cc61dc59150fcd0eec5b84cd4
https://doi.org/10.3109/0284186x.2014.952386
https://doi.org/10.3109/0284186x.2014.952386
Publikováno v:
Cancer Research. 78:3122-3122
Introduction: The risk of recurrence after surgery for colon cancer is not only determined by cancer stage and molecular characteristics, but also by the tumor microenvironment. This study aims to assess the prognostic value of CD3+ and CD8+ T lympho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e272a5255127234bc3306296d4c8c716
https://doi.org/10.1158/1538-7445.am2018-3122
https://doi.org/10.1158/1538-7445.am2018-3122